Condition: Medulloblastoma Recurrent · Ependymoma Recurrent · ATRT Recurrent · Sponsor: Medical University of Vienna
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenesis therapy has emerged as a new treatment option in solid malignancies. The frequent delivery of low doses of chemotherapy, referred to as metronomic or antiangiogenic chemotherapy, targets endothelial cells while reducing the toxicity associated with standard dose chemotherapy. The aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, ependymoma, ATRT, and CNS tumors of various histologies, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The study will be conducted in independent strata. Stratum I (recurrent medulloblastoma): recently completed (Peyrl, 2023). Stratum II (recurrent ependymoma), III (recurrent ATRT) and V (recurrent CNS tumors of various histologies, patients with exclusion criteria and adult patients): The primary objective is to determine the response rate defined as the percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or lack of recurrence at 6 months after start of antiangiogenic treatment. Stratum IV (recurrent medulloblastoma): To determine whether temozolomide, irinot…
This description comes directly from the study's public registry record.
Andreas Peyrl, MD · +43 1 40400 · andreas.peyrl@meduniwien.ac.at
Amedeo A Azizi, MD · +43 1 40400 · amedeo.azizi@meduniwien.ac.at
Always discuss trial participation with your own doctor first.
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Terminated |
| Dana-Farber Cancer Institute and Boston Children's Hospital | Boston, Massachusetts, United States | Terminated |
| Helen DeVos Children's Hospital | Grand Rapids, Michigan, United States | Recruiting |
| Dell Children's Medical Group SFC-HEM/ONC | Austin, Texas, United States | Recruiting |
| Medical University of Graz | Graz, Austria | Recruiting |
| Medical University of Innsbruck | Innsbruck, Austria | Recruiting |
| Kepler Universitätsklinikum Med Campus IV | Linz, Austria | Recruiting |
| Salzburger Universitätsklinikum | Salzburg, Austria | Recruiting |
| Medical University of Vienna | Vienna, Austria | Recruiting |
| University Hospital Brno | Brno, Czechia | Recruiting |
| Motol University Hospital Prague | Prague, Czechia | Recruiting |
| University hospital Rigshospitalet | Copenhagen, Denmark | Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT01356290